Seth Harmon
Director of Finance/CFO bei VIRIDIAN THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Seth Harmon is currently the Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. Prior to his current position, he served as the Chief Financial Officer at BioNTech SE from 2020 to 2023.
Before that, he was the Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed his undergraduate degree at Bowdoin College and holds a graduate degree in MBA from Northeastern University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.11.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Seth Harmon
| Unternehmen | Position | Beginn |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Director of Finance/CFO | 12.09.2023 |
Ehemalige bekannte Positionen von Seth Harmon
| Unternehmen | Position | Ende |
|---|---|---|
| BIONTECH SE | Director of Finance/CFO | 01.05.2023 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01.05.2020 |
Ausbildung von Seth Harmon
| Bowdoin College | Undergraduate Degree |
| Northeastern University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIONTECH SE | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
